Tuesday, July 21, 2026
🇺🇸 FDA

pharma · TTR-mediated Amyloidosis · Hypertension · ALNY

Alnylam Netherlands

Alnylam Netherlands B.V.

Alnylam Netherlands patent portfolio — 34 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Cambridge, USA HQ
2002 Founded
2,826 Employees
Public company Type
ALNY · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2002
Employees
2,826
Programs
1
Drugs
24
Patents
34
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Alnylam Netherlands patents

34 pharmaceutical patents indexed for Alnylam Netherlands. 0 expire within 24 months.

Alnylam Netherlands has 34 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

34 patents

Patent portfolio

  1. US 12049628

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11446380

    Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

    Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11401517

    Modified double-stranded RNA agents

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11286486

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11261447

    Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11079379

    Methods of treating transthyretin (TTR) mediated amyloidosis

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11028392

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10851377

    Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10806791

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10683501

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10612024

    Modified double-stranded RNA agents

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10612027

    Modified double-stranded RNA agents

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10570391

    RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10478500

    Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10240152

    Compositions and methods for inhibiting expression of transthyretin

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10208307

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10131907

    Glycoconjugates of RNA interference agents

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10125369

    PCSK9 iRNA compositions and methods of use thereof

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10119143

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9631193

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9399775

    RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

    Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9376680

    Serpinc1 iRNA compositions and methods of use thereof

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9370581

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9370582

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9234196

    Compositions and methods for inhibiting expression of transthyretin

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9133461

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9127274

    Serpinc1 iRNA compositions and methods of use thereof

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8828956

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8809292

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8741866

    Compositions and methods for inhibiting expression of transthyretin

    Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8222222

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Expires Mon Jul 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8168775

    Compositions and methods for inhibiting expression of transthyretin

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8158601

    Lipid formulation

    Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8106022

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Alnylam Netherlands have?

34 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Alnylam Netherlands patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.